# Gout Market

> Gout Market Research Report Information By Treatment and Diagnosis (Diagnosis, Treatment (NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents, Others)), Application (Acute Gout, Chronic Gout), End User (Hospitals & Clinics, Specialty Centers, Others) and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 11.75%
- **2024:** $ 5.67 Billion
- **2025:** $ 6.33 Billion
- **2035:** $ 19.23 Billion
- **Key Players:** AstraZeneca (GB), Novartis (CH), Takeda (JP), Amgen(US), Sanofi (FR), Pfizer (US), Horizon Therapeutics (IE), Bristol-Myers Squibb (US)

**Report ID:** MRFR/HC/4453-CR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/gout-market-5909

---

## Market Summary

As per Market Research Future analysis, the Gout Market Size was estimated at 5.666 USD Billion in 2024. The Gout industry is projected to grow from 6.331 USD Billion in 2025 to 19.23 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 11.75% during the forecast period 2025 - 2035

## Market Drivers

### Increasing Prevalence of Gout

The rising incidence of gout is a notable driver in the Gout Market. Recent studies indicate that the prevalence of gout has been steadily increasing, particularly among older adults and those with comorbidities such as obesity and hypertension. This trend is likely attributed to lifestyle factors, including dietary habits and sedentary behavior. As more individuals are diagnosed with gout, the demand for effective treatment options and management strategies intensifies. The Gout Market is responding to this growing need by developing innovative therapies and medications aimed at alleviating symptoms and preventing flare-ups. Furthermore, the increasing prevalence of gout is expected to drive market growth, as healthcare providers seek to address the needs of a larger patient population.

### Rising Healthcare Expenditure

The increase in healthcare expenditure is influencing the Gout Market positively. As healthcare budgets expand, there is a greater focus on managing chronic conditions, including gout. This trend is particularly evident in developed regions, where healthcare systems are prioritizing the treatment of diseases that significantly impact quality of life. The allocation of funds towards gout management, including medications and patient education, is expected to enhance the accessibility of treatment options. Consequently, this rise in healthcare expenditure may lead to increased patient engagement and adherence to treatment regimens, ultimately driving growth in the Gout Market. The financial commitment to gout management reflects a broader recognition of the condition's impact on public health.

### Advancements in Diagnostic Techniques

The evolution of diagnostic methods plays a crucial role in the Gout Market. Enhanced diagnostic techniques, such as dual-energy computed tomography and advanced blood tests, have improved the accuracy of gout diagnoses. These advancements enable healthcare professionals to identify gout more effectively, leading to timely treatment interventions. As awareness of gout increases, the demand for precise diagnostic tools is likely to rise, further propelling the Gout Market. The ability to differentiate gout from other forms of arthritis is essential for appropriate management, and as diagnostic technologies continue to advance, the market is expected to expand. This trend suggests that improved diagnostics will not only enhance patient outcomes but also stimulate growth within the Gout Market.

### Increased Awareness of Lifestyle Factors

The growing awareness of lifestyle factors contributing to gout is a pivotal driver in the Gout Market. Public health campaigns and educational initiatives are shedding light on the relationship between diet, exercise, and gout management. As individuals become more informed about the impact of purine-rich foods and alcohol consumption on uric acid levels, there is a potential shift towards healthier lifestyle choices. This awareness may lead to a decrease in gout flare-ups and a subsequent demand for supportive therapies. The Gout Market is likely to benefit from this trend, as healthcare providers emphasize holistic management strategies that incorporate lifestyle modifications alongside pharmacological treatments. This multifaceted approach could enhance patient outcomes and foster a more comprehensive understanding of gout.

### Growing Investment in Research and Development

Investment in research and development is a significant driver of the Gout Market. Pharmaceutical companies are increasingly allocating resources to discover new therapies and treatment modalities for gout. This focus on innovation is driven by the need for more effective medications that can address the underlying causes of gout, such as hyperuricemia. Recent data indicates that The Gout Market is projected to witness substantial growth, with a compound annual growth rate of over 6% in the coming years. This investment in R&D is likely to yield novel treatment options, enhancing the Gout Market's ability to meet patient needs and improve quality of life for those affected by gout.

## Future Outlook

The Gout Market is projected to grow at an 11.75% CAGR from 2025 to 2035, driven by increasing prevalence, advancements in treatment options, and rising awareness.

**New opportunities:**

- Development of personalized medicine for gout management
- 
- Expansion of telehealth services for remote patient monitoring
- Investment in innovative dietary supplements targeting uric acid reduction

By 2035, the Gout Market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased patient engagement.

## Segment Insights

### By Treatment: Urate-Lowering Agents (Largest) vs. NSAIDs (Fastest-Growing)

The Gout Market is primarily driven by Urate-Lowering Agents, which command a substantial share of the market due to their effectiveness in managing hyperuricemia and preventing gout attacks. NSAIDs hold a significant place in treatment options and are favored for immediate symptom relief during acute gout flares. Colchicine and corticosteroids, while essential, occupy smaller segments, as they are often used in specific situations and have seen a slow decline in preference against the growing acceptance of urate-lowering therapies.

Urate-Lowering Agents (Dominant) vs. NSAIDs (Emerging)

Urate-Lowering Agents are critical in the long-term management of gout, as they not only provide symptomatic relief but also actively reduce uric acid levels to prevent future attacks. Medications like allopurinol and febuxostat have become pivotal in therapy guidelines, showcasing their dominance in the Gout Market. In contrast, NSAIDs, while still popular for their immediate analgesic effect during flare-ups, are increasingly seen as an emerging option due to their rapid effectiveness. Despite their longstanding use, the growing risk of side effects and the emergence of more targeted treatments has slightly diminished their stronghold in the gout treatment landscape.

### By Application: Acute Gout (Largest) vs. Chronic Gout (Fastest-Growing)

In the Gout Market, Acute Gout remains the largest segment, accounting for a significant portion of overall market share due to its prevalence. Acute Gout affects a larger number of individuals, frequently triggered by dietary choices and lifestyle factors. This results in a substantial demand for effective therapies and management strategies aimed at rapid symptom relief. Conversely, the Chronic Gout segment is experiencing robust growth, fueled by an increasing awareness of the condition and the long-term management of gout flares. With advancements in treatment options, more patients are seeking to manage chronic conditions efficiently.

Acute Gout (Dominant) vs. Chronic Gout (Emerging)

Acute Gout is characterized by sudden episodes of intense pain, swelling, and inflammation, primarily affecting the joints, often the big toe. The dominance of Acute Gout in the market stems from its higher incidence rate and the immediate need for intervention. On the other hand, Chronic Gout, marked by persistent symptoms and recurrent flares, is emerging rapidly due to heightened awareness and improved treatments that allow sustained management. Patients with Chronic Gout are increasingly turning to long-term solutions that help reduce the frequency of flares, thus promoting a shift in treatment paradigms and indicating a growing market potential for chronic management solutions.

### By End User: Hospitals & Clinics (Largest) vs. Specialty Centers (Fastest-Growing)

In the Gout Market, the distribution among end user segments showcases that Hospitals & Clinics hold a significant share, serving as the primary treatment centers for patients with gout. These facilities benefit from established infrastructures and a broad range of healthcare services, making them the go-to choice for many patients seeking gout management. Additionally, Specialty Centers are emerging rapidly in this market, focusing specifically on gout and other related rheumatological conditions, capturing a growing share of the Gout Market due to their targeted expertise. The growth trends for both segments indicate a notable shift towards Specialty Centers, which are gaining traction as patients seek more personalized and specialized care. The rising prevalence of gout and the increasing awareness regarding its management are driving patients towards these dedicated units. Moreover, advancements in treatment methodologies and an uptick in lifestyle diseases are expected to further elevate the demand for these specialized care facilities in the coming years.

Hospitals & Clinics (Dominant) vs. Specialty Centers (Emerging)

Hospitals & Clinics, recognized as the dominant players in the Gout Market, offer a comprehensive array of services and are well-equipped to manage complicated cases and emergencies associated with gout. Their vast patient networks and existing healthcare frameworks allow them to provide extensive treatment options. Conversely, [Specialty](https://www.marketresearchfuture.com/reports/specialty-medical-chairs-market-7620) Centers are emerging as crucial players focusing directly on gout treatment, providing innovative solutions and personalized care that some larger hospitals may lack. The growing demand for specialized knowledge and treatment presents a significant opportunity for these centers to expand their market share and cater efficiently to the specific needs of gout patients.

## Regional Market Share Analysis

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World.

The North America region segmented into US, and Canada. The North America region held the largest market share in the Gout Market and market is accounted for USD 1.80 billion in 2022 and is expected to exhibit a 12.03% CAGR during the study period. Further, in the North America region the US gout market accounted for the largest market share. This is attributed to the increasing prevalence of gout, growing adoption of biologics, and rising R&D activities on regenerative medicines.

Moreover, the growing awareness about the health & accessibility of new treatment methods, the presence of well-developed healthcare infrastructure, and the rapid adoption of advanced medical technologies in the region drive the regional market growth during the forecast period.

In 2021, as per the Journal of the American Medical Association (JAMA) Network, an estimated 9.2 million people are affected by gout in the US, and it is more common in men and older people. The rising prevalence of gout demands effective treatment such as NSAIDs, corticosteroids, colchicine, urate-lowering agents, and others for treating this condition. In addition, the rising product launches are also contributing to market growth over the forecast period.

Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 3: Gout Market Share By Region 2022 (USD Billion)**

Europe gout market is expected to account for the second-largest market share due to the accessibility to advanced diagnosis & treatment facilities, the rising geriatric population prone to gout is driving up demand for effective treatment & therapeutics, and growing healthcare expenditure. For instance, according to the Eurostat database, healthcare expenditure was USD 176.61 billion in 2021.

Owing to rising healthcare expenditure also increases the company activities and government initiatives in developing effective diagnoses and treatment & therapeutics for gout, the Italy gout market is expected to be fastest growing market in the European region, followed by UK gout market. These factors are anticipated to positively impact the growth of the gout market. Additionally, improving government initiatives & healthcare frameworks and the presence of government organizations are boosting the growth of the gout market in Europe.

The Asia-Pacific gout market is expected to grow at a CAGR of 13.12% from 2023 to 2032. This is due to factors such as improving healthcare infrastructure, growing investment by major players with local manufacturers, and the increasing patient population suffering from gout. For instance, according to the Australian Bureau of Statistics, in 2018, an estimated 4.5% of Australians have gout. Gout Market is more common in males than females almost 8 in 10 (79%) people with gout are males.

Hence, the rise in patients suffering from gout drives the market growth in the region as gout medications such as allopurinol, febuxostat, and probenecid among others are extensively used to reduce uric acid levels in the blood. 

This can help reduce the number of future flares and make them less severe. Additionally, the availability of technical expertise, reduced cost of labor, and funding from governments for R&D investment to accelerate new product development have made Asia-Pacific the most favored region for outsourcing manufacturing services.

The Rest of the World includes the Middle East, Africa, and Latin America. Middle East hold the major market share in middle east and Africa region due to limited healthcare infrastructure, a dearth of awareness regarding the symptoms of the disease, and a lack of skilled professionals to manufacture gout therapeutics drugs are restricting the growth of the gout market in Sub-Saharan Africa. Additionally, low healthcare expenditure and unstable political situations are also affecting the market growth to an extent in the Middle East.

However, growing healthcare infrastructure, increasing government initiatives for improving the healthcare sector, and the growing geriatric population in the Middle East region are likely to favor market growth.

## Competitive Benchmarking

The Gout Market is distinguished by the presence of numerous global, regional, and local players catering to the increasing prevalence of gout, rising healthcare expenditure, and increasing research and development activities. However, the side effects of gout therapeutic drugs and the lack of awareness among people may hamper the growth of the Gout Market. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their products to broaden their reach.The Gout Market is extremely competitive, with players competing, partnering, and investing heavily in research and development to gain a significant market share. The Gout Market is moderately fragmented with rising competition, product launches, increasing collaborative partnerships, and other strategic decisions to achieve operational efficiency.The business model developed by manufacturers in the Gout Market includes offering high-quality products. The growth of prominent industry players is dependent on various factors, such as market conditions, government support, and industry development. Key players in the gout market are focusing on offering high-quality products to their customers. It is also projected that a rising number of strategic initiatives will boost the market's growth in the upcoming future.

## Recent News & Developments

**March 2023**: Selecta Biosciences, Inc revealed positive results for the Phase 3 DISSOLVE I & II placebo-controlled randomized clinical trials of SEL-212. SEL-212 is used for chronic refractory gout.

**July 2022**: The company received expanded FDA approval for Krystexxa for patients with uncontrolled gout. It is used in combination with immunotherapy and chemotherapy drug, [methotrexate](https://www.marketresearchfuture.com/reports/methotrexate-market-33602).

**July 2022:** ROMEG Therapeutics, LLC (US) and Scilex Holding Company (US) enters into an agreement for an exclusive license to market Gloperba, an FDA-approved preventative medication for excruciating gout flare-ups in adults, in the US.

**April 2019:** The U.S. Food and Drug Administration (FDA) has approved GLOPERBA (colchicine) to treat adult gout flare-ups.

**March 2022:** the United States Food and Drug Administration approved Strides Pharma's Colchicine tablets USP, 0.6 mg, used for the treatment and prevention of gout.

## Report Scope

| MARKET SIZE 2024 | 5.666(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 6.331(USD Billion) |
| MARKET SIZE 2035 | 19.23(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.75% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | AstraZeneca (GB), Novartis (CH), Takeda (JP), Amgen (US), Sanofi (FR), Pfizer (US), Horizon Therapeutics (IE), Bristol-Myers Squibb (US) |
| Segments Covered | Treatment and Diagnosis |
| Key Market Opportunities | Emerging biologics and personalized medicine are transforming treatment approaches in the Gout Market. |
| Key Market Dynamics | Rising prevalence of gout drives demand for innovative therapies and personalized treatment approaches in the pharmaceutical sector. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Gout Market as of 2024?**
A: The Gout Market was valued at 5.666 USD Billion in 2024.

**Q: What is the projected market size for the Gout Market in 2035?**
A: The Gout Market is projected to reach 19.23 USD Billion by 2035.

**Q: What is the expected CAGR for the Gout Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Gout Market during 2025 - 2035 is 11.75%.

**Q: Which companies are the key players in the Gout Market?**
A: Key players in the Gout Market include AstraZeneca, Novartis, Takeda, Amgen, Sanofi, Pfizer, Horizon Therapeutics, and Bristol-Myers Squibb.

**Q: What are the main treatment segments in the Gout Market?**
A: The main treatment segments in the Gout Market include NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents, and Others.

**Q: How much is the Urate-Lowering Agents segment expected to grow by 2035?**
A: The Urate-Lowering Agents segment is expected to grow from 2.0 USD Billion in 2024 to 8.0 USD Billion by 2035.

**Q: What is the market size for Acute Gout applications in 2024?**
A: The market size for Acute Gout applications was 2.833 USD Billion in 2024.

**Q: What is the projected market size for Chronic Gout applications by 2035?**
A: The projected market size for Chronic Gout applications is expected to reach 9.615 USD Billion by 2035.

**Q: Which end-user segment is anticipated to have the highest growth in the Gout Market?**
A: The Hospitals & Clinics segment is anticipated to grow from 2.5 USD Billion in 2024 to 8.5 USD Billion by 2035.

**Q: What is the expected growth for the Specialty Centers segment in the Gout Market?**
A: The Specialty Centers segment is expected to grow from 1.5 USD Billion in 2024 to 5.5 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/gout-market-5909*